{
    "organizations": [],
    "uuid": "781ee76f465940621e0724999c737ba65ba800ff",
    "author": "",
    "url": "https://in.reuters.com/video/2018/04/30/look-for-ma-activity-in-biotech-says-kev?videoId=422713252",
    "ord_in_thread": 0,
    "title": "Look for M&A activity in biotech, says Kevin Mahn",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Look for M&A activity in biotech, says Kevin Mahn 12:35am IST - 05:32\nHennion & Walsh's CIO tells Reuters' Fred Katayama biotech firms with drugs already in the pipeline are prime acquisition targets for big drug makers.\nHennion & Walsh's CIO tells Reuters' Fred Katayama biotech firms with drugs already in the pipeline are prime acquisition targets for big drug makers. //reut.rs/2r6jQ06",
    "published": "2018-04-30T22:05:00.000+03:00",
    "crawled": "2018-04-30T22:42:07.017+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "look",
        "activity",
        "biotech",
        "say",
        "kevin",
        "mahn",
        "ist",
        "hennion",
        "walsh",
        "cio",
        "tell",
        "reuters",
        "fred",
        "katayama",
        "biotech",
        "firm",
        "drug",
        "already",
        "pipeline",
        "prime",
        "acquisition",
        "target",
        "big",
        "drug",
        "maker",
        "hennion",
        "walsh",
        "cio",
        "tell",
        "reuters",
        "fred",
        "katayama",
        "biotech",
        "firm",
        "drug",
        "already",
        "pipeline",
        "prime",
        "acquisition",
        "target",
        "big",
        "drug",
        "maker"
    ]
}